- Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University.
- The financing will enable Nova Anchora to advance its lead candidate NvA-011, a recombinant collagen therapy, through IND-enabling studies.
- The investment underscores the backers’ commitment to advancing life-changing treatments for Epidermolysis bullosa, a rare and debilitating skin disorder.
MUNICH, Germany and SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) — DEBRA Research gGmbH, a German non-profit organization dedicated to advancing research and drug development for those affected by Epidermolysis bullosa (EB), is investing alongside Viking Global Investors, CureEB, EBMRF, and Stanford University, in Nova Anchora LLC, an early-stage, preclinical biotech company focused on developing…
